News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,026 Results
Type
Article (8016)
Company Profile (140)
Press Release (476869)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166749)
Career Advice (305)
Deals (25740)
Drug Delivery (7)
Drug Development (52877)
Employer Resources (14)
FDA (9760)
Job Trends (8575)
News (238198)
Policy (17908)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33155)
ALS (105)
Alzheimer's disease (979)
Antibody-drug conjugate (ADC) (272)
Approvals (10389)
Artificial intelligence (324)
ASCO (159)
Autoimmune disease (208)
Automation (28)
Bankruptcy (263)
Best Places to Work (6959)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (112)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (514)
Cancer (3681)
Cardiovascular disease (221)
Career advice (245)
Career pathing (1)
CAR-T (175)
CDMO (7)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (34)
Clinical research (47920)
Collaboration (1253)
Commercialization (3)
Compensation (1474)
Complete response letters (34)
COVID-19 (757)
CRISPR (64)
C-suite (759)
Cystic fibrosis (85)
Data (5712)
Denatured (4)
Depression (102)
Dermatology (63)
Diabetes (344)
Diagnostics (4196)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73730)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87716)
Executive appointments (703)
FDA (12423)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (927)
Gene editing (126)
Generative AI (9)
Gene therapy (321)
GLP-1 (291)
Government (945)
Grass and pollen (2)
Guidances (281)
Healthcare (9328)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (59)
Indications (157)
Infectious disease (945)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (258)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (11)
Liver cancer (44)
Longevity (18)
Lung cancer (512)
Lymphoma (253)
Machine learning (27)
Management (3)
Manufacturing (538)
Marketing (8)
MASH (118)
Medical device (8664)
Medtech (8811)
Mergers & acquisitions (14393)
Metabolic disorders (709)
mRNA (59)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (40)
Neuroscience (1834)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (225)
Opinion (10)
Ovarian cancer (160)
Pain (172)
Pancreatic cancer (201)
Parkinson's disease (201)
Partnered (12)
Patents (480)
Patient recruitment (513)
Peanut (31)
People (41256)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15475)
Phase 2 (21396)
Phase 3 (14427)
Pipeline (7439)
Policy (18)
Postmarket research (1570)
Preclinical (6541)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3020)
Recruiting (6)
Regulatory (14867)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (157)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (330)
Venture capital (17)
Weight loss (73)
Women's health (82)
Date
Today (53)
Last 7 days (260)
Last 30 days (1494)
Last 365 days (18952)
2026 (12604)
2025 (19251)
2024 (22997)
2023 (26562)
2022 (34598)
2021 (37172)
2020 (33484)
2019 (23258)
2018 (17494)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20441)
2010 (20333)
Location
Africa (228)
Alabama (74)
Alaska (2)
Arizona (307)
Arkansas (11)
Asia (17959)
Australia (2099)
California (12057)
Canada (3172)
China (530)
Colorado (487)
Connecticut (413)
Delaware (208)
Europe (24653)
Florida (1805)
Georgia (386)
Hawaii (3)
Idaho (46)
Illinois (707)
India (51)
Indiana (316)
Iowa (15)
Japan (409)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1206)
Massachusetts (7896)
Michigan (308)
Minnesota (563)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (117)
New Hampshire (60)
New Jersey (2635)
New Mexico (12)
New York (2829)
North Carolina (1291)
North Dakota (4)
Northern California (6048)
Ohio (280)
Oklahoma (14)
Oregon (18)
Pennsylvania (2265)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5008)
Tennessee (121)
Texas (1957)
United States (39122)
Utah (363)
Vermont (1)
Virginia (155)
Washington D.C. (38)
Washington State (933)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,026 Results for "lunit inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT
Lunit announced that it has received U.S. Food and Drug Administration 510 clearance for its 3D Breast Tomosynthesis AI solution, Lunit INSIGHT DBT.
November 14, 2023
·
3 min read
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit’s AI-powered analyzer for quantitative immune phenotyping from H&E.
March 26, 2024
·
5 min read
Deals
Volpara Health enters agreement to be acquired by Lunit, Inc.
Volpara Health Technologies (“Volpara,” “the Group,” or “the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, is pleased to announce it has entered into an agreement to be acquired by Lunit Inc.
December 13, 2023
·
3 min read
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, proudly announces the successful completion of its acquisition of Volpara Health Technologies, a global leader in medical software for breast cancer screening.
May 22, 2024
·
4 min read
Genetown
Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings
Boston Imaging announced that Samsung has signed a supply contract with Lunit Inc., a leading provider of artificial intelligence powered solutions for cancer diagnostics and therapeutics, to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
January 25, 2024
·
5 min read
Deals
Update on Lunit’s Acquisition of Volpara: New Zealand High Court Initial Approval Secured
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a significant update on its acquisition of Volpara Health Technologies.
March 13, 2024
·
4 min read
Lunit’s AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists’ workload while enhancing cancer detection rates.
April 8, 2024
·
3 min read
Lunit to Advance Singapore’s Healthcare System with AI-powered Solution for Medical Imaging
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, partners with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore’s public healthcare system.
November 30, 2023
·
4 min read
Lunit Secures $150 Million in Capital Increase
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the successful completion of a significant paid-in capital increase of $150 million.
November 15, 2023
·
2 min read
Lunit’s AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection - published in European Radiology
Lunit today announced that in a study recently published in European Radiology, Lunit’s AI-powered mammography analysis solution, Lunit INSIGHT MMG, has been validated for its effectiveness in standalone breast cancer detection.
November 22, 2023
·
3 min read
1 of 48,503
Next
